Cipla Medpro partnered with Serum Institute India to provide Vaccines in South Africa

292

Who: Cipla Medpro and Serum Institute India
What: Partnered
When: 8 October 2015
Why: To provide Vaccines in South Africa

Drug maker Cipla on 8 October 2015 announced that its South African subsidiary Cipla Medpro (Pty) Ltd. has entered into an exclusive agreement with Serum Institute of India (SII). The two organizations have partnered to provide vaccines in South Africa.

The partnership will enable affordable and accessible vaccines for South Africans as well as will facilitate a reliable supply stream to the South African Government.

About Cipla Medpro (Pty) Ltd
Cipla Medpro, the third largest pharmaceutical manufacturer in South Africa, is a leading provider of affordable medicines to the public and private sectors. Cipla Medpro manufactures world class pharmaceuticals at cost-effective prices, making quality medicines affordable, and advancing healthcare for all South Africans.

About Serum Institute of India Limited (SII)
Serum Institute of India Limited is the world’s second largest vaccine manufacturer in number of doses manufactured and supplied to more than 140 countries. The vaccines include Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, Rubella, Meningitis A, Influenza and Polio vaccines. One of every two children born in the world receives a vaccine manufactured by Serum Institute.